Use of tea extracellular vesicles in preparing medicine for treating atopic dermatitis

By preparing and applying tea leaf extracellular vesicles as a specific dermatitis treatment drug, the problem of large side effects of existing drugs is solved, and a dermatitis treatment solution with fewer side effects and more effective results is provided.

CN118021883BActive Publication Date: 2024-11-05FUJIAN XIANGLAN TEA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410203406.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-23
Publication Date
2024-11-05
Estimated Expiration
2044-02-23

AI Technical Summary

Technical Problem

Existing medications for atopic dermatitis have significant side effects, and long-term use can lead to local skin problems. There is an urgent need to develop treatments with fewer side effects.

Method used

Tea extracellular vesicles are used as a raw material for the treatment of atopic dermatitis. The tea extracellular vesicles are prepared and purified through enzymatic hydrolysis, filtration, dialysis and ultracentrifugation, and then made into topical dosage forms such as microneedles and topical liquids for skin treatment.

Benefits of technology

Tea cell extracellular vesicles significantly reduced the number of scratches and the thickness of ear swelling in mice with atopic dermatitis, and lowered the back score index. They have similar therapeutic effects to conventional drugs but with fewer side effects and are easily absorbed by the skin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118021883B_ABST
    Figure CN118021883B_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of the use of tea extracellular vesicles, and specifically discloses a therapeutic use of tea extracellular vesicles for atopic dermatitis. The tea extracellular vesicles are derived from any one or both of tea leaves and stems; the preparation method is as follows: step one, take any one or both of tea leaves and stems, crush and enzymatically hydrolyze, collect the supernatant after solid-liquid separation, and obtain tea juice; step two, filter, dialyze and microfilter the tea juice, and collect the filtrate; step three, concentrate, purify and ultracentrifuge the filtrate to obtain tea extracellular vesicles. The present application found that tea extracellular vesicles have therapeutic uses for atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of uses of tea extracellular vesicles, and more specifically, to the therapeutic use of tea extracellular vesicles for atopic dermatitis. Background Art

[0002] Atopic dermatitis (AD) is an inflammatory skin disease with severe itching, which has the characteristics of complex pathogenesis, high incidence and easy recurrence. Currently, moisturizers, topical corticosteroids and immunosuppressants are commonly used for anti-inflammatory treatment of such skin lesions. These local treatments can relieve the symptoms of AD; however, long-term use can cause side effects such as rash, tingling and atrophy of the local skin. Therefore, we urgently need to develop better AD treatment drugs without systemic exposure and related side effects.

[0003] Among them, plant-derived extracellular vesicles (PDEVs) have attracted increasing interest in the scientific community. The reason is that some studies have shown that plant-derived extracellular vesicles contain functional biomolecules such as proteins, RNA, metabolites, and lipids, and PDEVs may affect mammalian cells. More and more studies have shown that PDEVs have anti-cancer, anti-inflammatory, and antioxidant activities, making them attractive in the treatment of diseases.

[0004] Tea is made from the young leaves or buds of the Camellia plant of the Theaceae family. As a healthy beverage, tea has a long history of drinking. Tea contains a variety of biologically active substances, such as tea polyphenols, catechins, and theaflavins, which have many biological functions such as antioxidant, anti-tumor, antibacterial and anti-inflammatory, among which the anti-inflammatory activity of tea is particularly significant.

[0005] Therefore, it is necessary to develop the therapeutic use of tea extracellular vesicles for atopic dermatitis, which will provide a product for treating atopic dermatitis with fewer side effects. Summary of the invention

[0006] The present application provides a therapeutic use of tea extracellular vesicles for atopic dermatitis. Studies have shown that tea extracellular vesicles have the effect of treating atopic dermatitis.

[0007] The therapeutic use of tea extracellular vesicles for atopic dermatitis provided in this application adopts the following technical scheme:

[0008] The invention discloses a therapeutic use of tea leaf extracellular vesicles for atopic dermatitis, wherein the tea leaf extracellular vesicles are derived from any one or both of tea leaf leaves and stem leaves.

[0009] By adopting the above technical scheme, the present application found through animal experiments that 0.5wt% DNFB solution was applied to the back and right ear of mice to induce atopic dermatitis in mice. Subsequently, on this basis, the mice were immediately gavaged with 200μL of the tea extracellular vesicle solution of the present application, with a concentration of 0.5μg / μL (ethanol: saline = 1:99). The results showed that the number of scratching times of mice administered with the tea extracellular vesicles of the present application within 10 minutes after modeling was significantly reduced compared with the mice in the modeling group (only inducing atopic dermatitis but not administering any therapeutic drugs), the thickness of ear swelling was significantly reduced, and the back score index was also significantly reduced; all of the above indicate that the tea extracellular vesicles of the present application have the use of treating atopic dermatitis. The H&E staining experiment of related tissues also proved a similar effect. Compared with conventional atopic dermatitis treatment drugs, such as dexamethasone, the tea extracellular vesicles of the present application have similar therapeutic effects on atopic dermatitis and have the advantages of natural raw materials and low side effects.

[0010] Optionally, the method for preparing tea extracellular vesicles comprises the following steps:

[0011] Step 1, taking any one or both of tea leaves and stems, crushing and then performing enzymolysis, collecting the supernatant after solid-liquid separation, and obtaining tea juice;

[0012] Step 2, filtering, dialyzing and microfiltering the tea juice, and collecting the filtrate;

[0013] Step 3: Concentrate, purify and ultracentrifuge the filtrate to obtain tea extracellular vesicles.

[0014] By adopting the above technical solution, when preparing tea extracellular vesicles, tea cells include cell walls and cell membranes, and the cell walls are destroyed by enzymatic hydrolysis to release the extracellular vesicles in the cells. After the tea juice is treated in step 2, tea extracellular vesicles containing more impurities are obtained, and after further treatment in step 3, purified tea extracellular vesicles are obtained to improve its therapeutic effect on inflammatory bowel disease.

[0015] Optionally, the enzymatic hydrolysis in step 1 includes the following steps: soaking the crushed tea sample in an ethanol solution, removing the ethanol solution, adding enzyme solution and performing enzymatic hydrolysis at 45-55° C. for 5-7 hours.

[0016] By adopting the above technical solution, the immersion treatment with ethanol solution can, on the one hand, destroy the cell structure of tea leaves and change their permeability; on the other hand, it can also dissolve impurities such as lipids.

[0017] Optionally, the components of the enzyme solution include: 1.5-2.5wt% pectinase, 3-5wt% cellulase, and 0.4-0.8mol / L mannitol.

[0018] In some embodiments, the pectinase content is 1.5-1.8wt%, 1.7-2.1wt%, 1.9-2.4wt% and 2.5-2.5wt%; in one embodiment, the pectinase content can be 1.5wt%, 1.64wt%, 1.82wt%, 1.93wt%, 2.06wt%, 2.32wt% and 2.47wt%.

[0019] In some embodiments, the cellulase content is 3-3.8wt%, 3.6-4.2wt%, 4.1-4.7wt% and 4.6-5.0wt%; in one embodiment, the cellulase content can be 3.1wt%, 3.64wt%, 3.92wt%, 4.21wt%, 4.52wt%, 4.82wt% and 5.0wt%.

[0020] In some embodiments, the mannitol content is 0.4-0.51 mol / L, 0.48-0.59 mol / L, 0.52-0.67 mol / L, 0.64-0.79 mol / L, 0.76-0.84 mol / L and 0.81-0.9 mol / L; in one embodiment, the mannitol content can be 0.41 mol / L, 0.46 mol / L, 0.57 mol / L, 0.62 mol / L, 0.74 mol / L and 0.89 mol / L.

[0021] Optionally, the volume fraction of ethanol in the ethanol solution is 70-80%.

[0022] Optionally, the filtration in step 2 includes filtration with a filter screen or filter bag with a pore size range of 250-350 mesh, and collecting the filtrate; the dialysis includes filtration with a membrane with a pore size of 100-200nm, and collecting the dialysate; the microfiltration includes filtration with a membrane with a pore size of 0.4-0.55μm, and collecting the filtrate.

[0023] By adopting the above technical solution, large particle impurities are gradually removed with gradually decreasing membrane pore size to enrich and purify tea extracellular vesicles.

[0024] Optionally, the purification in step three includes the steps of purifying through a size exclusion chromatography column and collecting the eluate.

[0025] Optionally, the ultracentrifugation in step 3 specifically comprises the following steps:

[0026] The eluate during purification is centrifuged at 1500-2500g for 25-35min; the supernatant is centrifuged at 8000-12000g for 40-50min and then microfiltered; the filtrate is centrifuged at 80000-120000g for 65-75min; the precipitate is resuspended in PBS buffer and centrifuged at 80000-120000g for 65-75min to obtain tea extracellular vesicles.

[0027] By adopting the above technical scheme, the eluate is centrifuged at 1500-2500g for 25-35 minutes to precipitate the macromolecules, and the tea extracellular vesicles remain in the supernatant; the centrifugal speed is further increased, and after centrifugation at 8000-12000g for 40-50 minutes, impurities with smaller particle sizes are further removed and precipitated, while the tea extracellular vesicles still remain in the supernatant; the filtrate after microfiltration is centrifuged at 80000-120000g for 65-75 minutes, at which time the tea extracellular vesicles are precipitated, while impurities with smaller molecular weight are retained in the supernatant, the precipitate is resuspended with PBS buffer and then centrifuged at 80000-120000g for 65-75 minutes, and the small molecule precipitate is further removed to obtain the tea extracellular vesicles.

[0028] Optionally, when the tea extracellular vesicles are used for atopic dermatitis, the tea extracellular vesicles are a drug raw material or one of the drug raw materials that exerts a therapeutic effect;

[0029] The dosage form of the drug is selected from any one or more of microinjections, external liquid preparations, external solid preparations, external semisolid preparations, plasters, patches and external gas preparations.

[0030] By adopting the above technical solution, the tea extracellular vesicles can be prepared into a medicine that is convenient for external application and coating according to actual drug needs.

[0031] Furthermore, the external liquid agent may be any one or more of a solution, a lotion, an ointment and a tincture; the external solid agent may be an external powder; the external semisolid agent may be any one or more of an ointment, a gel and a cream; the patch may be a gel patch or a rubber patch; the external gas preparation may be an aerosol or a spray.

[0032] Optionally, the medicine further comprises other auxiliary components, and the other auxiliary components are selected from one or more of probiotics, adjuvants, excipients, auxiliary agents, dispersants and pharmaceutical additives.

[0033] In summary, this application has the following beneficial effects:

[0034] 1. The present application provides the therapeutic use of tea extracellular vesicles for atopic dermatitis. Experiments have shown that tea extracellular vesicles have a good improvement effect on atopic dermatitis and have the potential to prepare natural medicine products for the treatment of atopic dermatitis, which to a certain extent solves the side effect problem of existing related drugs; and the nanoscale size of extracellular vesicles makes them easy to be absorbed and have better efficacy.

[0035] 2. The present application uses tea stems, leaves, rhizomes, etc. as raw materials for preparing tea extracellular vesicles. First, the tea extracellular vesicles are released outside the cells mainly through enzymatic hydrolysis, and then through multi-stage filtration (such as filter filtration, membrane filtration, microfiltration, etc.) and ultracentrifugation, finally obtaining tea extracellular vesicles with excellent effect and high purity. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 This is an electron microscopic image of tea extracellular vesicles obtained in this application;

[0037] Figure 2 It is the particle size distribution and concentration diagram of tea extracellular vesicles obtained in this application;

[0038] Figure 3 The scratching times, back lesion site scores and ear swelling thickness of the model mice within 10 minutes after the application of the tea extracellular vesicles of the present application, n = 5, * refers to p < 0.05, ** refers to p < 0.01, *** refers to p < 0.001, **** refers to p < 0.0001;

[0039] Figure 4 is a photo of the skin lesions on the back of mice after application of the tea extracellular vesicles of the present application;

[0040] Figure 5 This is a H&E section image of mouse skin and ear tissue after administration of the tea extracellular vesicles of the present application;

[0041] Figure 6 The extracellular vesicles of tea leaves were applied to the spinous area of ​​mouse skin and the spinous area of ​​ear. DETAILED DESCRIPTION

[0042] The present application is further described in detail below in conjunction with the accompanying drawings and examples. It is particularly noted that if no specific conditions are specified in the following examples, the experiments are carried out under conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, the raw materials used in the following examples can all be sourced from common commercial sources.

[0043] The cellulase involved in this application was purchased from source leaves, product model S100041; pectinase was purchased from source leaves, product model S10007; mannitol was purchased from Shanghai Biotechnology, product model A600335.

[0044] When the tea extracellular vesicles of the present application are used for atopic dermatitis, the tea extracellular vesicles are added to the drug as a drug raw material or one of the drug raw materials that exerts a therapeutic effect.

[0045] The dosage form of this type of drug is selected from any one or more of microinjections, external liquid preparations, external solid preparations, external semisolid preparations, plasters, patches and external gas preparations.

[0046] Furthermore, the external liquid agent may be any one or more of a solution, a lotion, an ointment and a tincture; the external solid agent may be an external powder; the external semisolid agent may be any one or more of an ointment, a gel and a cream; the patch may be a gel patch or a rubber patch; the external gas preparation may be an aerosol or a spray.

[0047] In order to prepare a preparation of a desired form, the drug further comprises other auxiliary components, which are selected from one or more of probiotics, adjuvants, excipients, auxiliary agents, dispersants and pharmaceutical additives.

[0048] Example

[0049] (I) A method for preparing tea extracellular vesicles, comprising the following steps:

[0050] Step 1: Take the tender stems and leaves of tea leaves, wash them clean, add an appropriate amount of PBS buffer, and then put them in a juicer to chop them (1mm×1mm), soak each 10g in a 75Vol.% ethanol solution (mix anhydrous ethanol and water in a volume ratio of 75:25) for 1 minute, then wash away the ethanol residue with distilled water, wipe dry with sterile paper, add 50mL of enzyme solution, enzymolyze at 50℃ for 6h, and then centrifuge at a speed of 10000rpm for 1h to allow the enzymolyzed tissue residue to settle, collect the supernatant, obtain tea juice, and store it at -80℃. The components of the enzyme solution are: 4wt% cellulase, 2wt% pectinase, 0.6mol / L mannitol, and the pH is 5.8.

[0051] Step 2: After filtering, dialysis and microfiltration of the tea juice, collect the filtrate. The specific operation steps are as follows:

[0052] The tea juice is coarsely filtered through a flange positive pressure filter bag, wherein the filter bag has a pore size of 300 meshes, and the filtrate is collected; the filtrate is finely filtered through a ceramic membrane, the membrane core pore size of the ceramic membrane is 100-200nm, the pressure during ceramic membrane filtration is 0.2MPa, and the dialysate is collected; the dialysate is filtered through a disc two-phase filter microporous membrane, the disc two-phase filter microporous membrane is made of PVDF, and the membrane pore size is 0.45μm, and the filtrate is collected.

[0053] Step 3: Concentrate the obtained filtrate by tangential flow (PES material, 100KD) and collect the concentrate. The concentrate is purified by size exclusion chromatography column (cross-linked agarose, CL-6B) and the eluate is collected. Centrifuge the eluate at 2000×g and 4°C for 30min. Carefully transfer the supernatant to a new centrifuge tube and centrifuge again at 10000×g and 4°C for 45min to remove larger vesicles. Take the supernatant and filter it through a 0.45μm filter membrane to collect the filtrate. Transfer the filtrate to a new centrifuge tube, select an ultraspeed rotor, and centrifuge at 4°C and 100000×g for 70min. Then remove the supernatant, resuspend with 10mL pre-cooled 1×PBS, select an ultraspeed rotor, and ultracentrifuge again at 4°C and 100000×g for 70min. Then remove the supernatant and resuspend with 150μL pre-cooled 1×PBS to obtain.

[0054] (II) Performance testing

[0055] 1. Electron microscopic observation of tea extracellular vesicles

[0056] Take out 10 μL of the extracellular vesicle solution prepared in step 3, then drop it on the copper mesh and let it settle for 1 minute, and then remove the floating liquid with filter paper. Add 10 μL of uranyl acetate and let it settle for 1 minute on the copper mesh. After removing the floating liquid with filter paper, dry it at room temperature for 3 minutes to prepare the sample to be tested. The sample to be tested was placed under 100 kV for transmission electron microscopy imaging. The results are shown in Figure 1 . Figure 1 The results showed that the tea extracellular vesicles obtained by this method had a particle size of 80-90nm, which was consistent with the particle size range of extracellular vesicles.

[0057] 2. Particle size analysis of tea extracellular vesicles

[0058] Take out 5 μL of the extracellular vesicle fluid prepared in step 3 and dilute it to 30 μL; after the instrument performance test is passed with the standard, load the extracellular vesicle fluid sample and perform gradient dilution to avoid the sample clogging the injection needle; obtain the particle size distribution and concentration information of the tea tree extracellular vesicles, see Figure 2 .from Figure 2 The results showed that the particle size of tea tree extracellular vesicles was mainly distributed in the range of 60-100 nm, and the concentration of tea tree extracellular vesicles was 2.53×10 10 / mL; the particle size and concentration of its exosomes belong to the category of exosomes, indicating that what is obtained is tea extracellular vesicles.

[0059] 3. Extracellular vesicle tracing experiment

[0060] Protein extraction and concentration determination of exosome samples

[0061] The extracellular vesicle solution prepared in step 3 was taken out and quickly added to 5×RIPA lysis buffer; after mixing, the solution was lysed on ice for 30 minutes, and mixed during the period; then, a standard sample for measuring protein concentration by BCA method was prepared, and 5 μL of the sample was added to the BCA mixed solution and mixed; finally, it was incubated at 37°C for 30 minutes, and the OD was measured on the microplate reader. 562nm The absorbance value was detected and recorded, and the protein concentration of the sample to be tested was further calculated based on the standard curve. The protein concentration of the sample to be tested was 150.83 μg / μL.

[0062] 4. Animal experiments

[0063] Dexamethasone, abbreviated as DXM; 4-nitrodiazonium fluoroborate, abbreviated as DNFB; Tealeaf-driven exosome-like nanoparticles, abbreviated as TELNs.

[0064] 4.1. 8-week-old BALB / c mice were divided into four groups: control group, DNFB group, DNFB+DXM group, and DNFB+TELNs group, with 5 mice in each group. Except for the control group, 100 μL of 1.0 wt% DNFB (acetone: olive oil = 3:1) was evenly applied to the depilatory area on the back of the mice for sensitization on the first day of the experiment. Sensitization was strengthened on the third day. From the second week to the fourth week, 0.5 wt% DNFB solution (50 μL on the back, 20 μL on the right ear) was evenly applied to the front and back of the back and right ear of the mice on the 7th, 10th, 14th, 17th, 21st, 24th, and 28th days of the experiment to induce dermatitis. The control group applied an equal volume of acetone olive oil matrix on the depilatory area on the back, and the treatment time node and dosage were the same as the other three groups. At the same time as modeling, the control group and DNFB group were gavaged with blank solvent (ethanol: saline = 1:99) at a rate of 0.1 mL / 10 g body weight, 3 times a week; the DNFB+DXM group was gavaged with 0.1 mg / kg dexamethasone (ethanol: saline = 1:99) at a rate of 0.1 mL / 10 g body weight, 3 times a week; the DNFB+TELNs group was gavaged with 200 μL TELNs at a concentration of 1.5 μg / μL (ethanol: saline = 1:99), 3 times a week.

[0065] On the 3rd, 10th, 17th and 24th days of modeling, the mice were sensitized with DNFB for 30 minutes with 50 μL of 0.5wt% DNFB (acetone: olive oil = 3:1) solution each time, and the number of scratching times within 10 minutes was recorded. 24 hours after sensitization, the skin lesions on the back of the mice were semi-quantitatively scored and evaluated according to the clinical manifestation standards, as follows: 0 point: no damage; 1 point: mild damage; 2 points: moderate damage; 3 points and above: severe damage. The damage evaluation was based on the following four clinical symptoms: (1) erythema; (2) edema / papules; (3) epidermal peeling / scratches; (4) dryness / scabs. On the 3rd, 10th, 17th and 24th days of the modeling experiment, an electronic screw micrometer was used to precisely measure the thickness of the same position on the right and left ears of the mice, and the thickness difference (μm) was used to reflect the ear swelling. For details, see Figure 3 .

[0066] The number of scratches within 10 minutes, the semi-quantitative scoring of the lesion site, and the thickness of ear swelling are all important indicators of atopic dermatitis. Figure 3 As shown in the figure, the number of scratching times, skin lesion scores and ear swelling thickness within 10 minutes in the DNFB group were significantly higher than those in the control group, with significant differences; the DNFB+DXM group and DNFB+TELNs group showed significant differences from the DNFB group, indicating that TELNs can alleviate the symptoms of atopic dermatitis in mice.

[0067] In addition, if Figure 4 As shown, on the 24th day, the back injury in the DNFB group was severe, while the back injury in the DNFB+DXM group and the DNFB+TELNs group was improved compared with that in the DNFB group.

[0068] 4.2 H&E staining

[0069] On the 29th day of the experiment, mice were killed and skin and ear tissue specimens were obtained. Before embedding, the tissues were washed overnight with running water to remove the residual fixative, and then dehydrated, transparentized and wax-impregnated according to the procedures in Table 1.

[0070] Table 1 Dehydration, transparency and wax dipping procedures

[0071] 50% ethanol 1h 75% ethanol 1h (or 4℃ long-term storage) 85% ethanol 30min 95% ethanol Ⅰ 30min 95% ethanol Ⅱ 90min 100% Ethanol I 10min 100% ethanol Ⅱ 10min Xylene Ⅰ 5min Xylene Ⅱ 5min Xylene Ⅲ 5min Paraffin I 20min Paraffin II 10min Paraffin III 10min

[0072] Paraffin sections were prepared with a section thickness of 5 μm. After the sections were cut, they were rinsed in 30% ethanol solution, spread in 48°C warm water, and baked in a 60°C constant temperature oven for 2 h. The sections were dewaxed and rehydrated according to the procedure in Table 2.

[0073] Table 2 Dewaxing and rehydration procedures for sections

[0074]

[0075]

[0076] The dewaxed and rehydrated materials were processed as follows: stain with hematoxylin solution for 5 minutes, then quickly wash with tap water; separate with 0.5% hydrochloric acid ethanol for 1-2 seconds, then quickly wash with distilled water; turn blue with 1% ammonia solution, immerse the slices in 1% ammonia solution until the tissue turns blue, wash with tap water for 30-60 seconds, and check the degree of separation of cell nuclei under a microscope; stain with 1% eosin for 15 seconds, then quickly wash with distilled water; quickly wash with 80%, 90%, and 95% ethanol solutions, 10 seconds each; monitor the color contrast between cell nuclei and cytoplasm under a microscope; wash with 100% ethanol twice, 1-2 minutes each time; wash with xylene twice, 1-2 minutes each time; finally seal with neutral gum; take pictures for archiving, observe the staining results, and calculate the skin epidermal thickness. For specific results, see Figure 5 and Figure 6 .

[0077] Among them, the results of H&E staining are as follows Figure 5 As shown in the figure, HE staining of colon tissue sections of mice in each group showed that the structures of the skin layers on the back of mice in the control group were clear, the epidermis and dermis structures were normal, and there was no obvious inflammatory cell infiltration between cells and within cells. Incomplete or excessive keratinization was observed in the lesions on the back of mice in the DNFB group, and the epidermis was significantly thickened, accompanied by a large number of inflammatory cells infiltration, and the lesions were obviously edematous; the DNFB+DXM group and the DNFB+TELNs group were improved compared with the DNFB group, and the DNFB+TELNs group was more effective.

[0078] Figure 6 The lesion area was significantly higher in the DNFB group than in the control group, and lower in the DNFB+TELNs group than in the DNFB group, indicating the improvement effect of TELNs on atopic dermatitis in mice.

[0079] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.

Claims

1. Use of tea extracellular vesicles in the preparation of a medicament for treating atopic dermatitis, It is characterized in that The method for preparing tea extracellular vesicles comprises the following steps: Step 1: Take any one or both of tea leaves and stems, crush them, perform enzymolysis, collect the supernatant after solid-liquid separation, and obtain tea juice; the enzymolysis comprises the following steps: soak the crushed tea sample in ethanol solution, remove the ethanol solution, add enzyme solution and perform enzymolysis at 45-55°C for 5-7h; Step 2, filtering, dialyzing and microfiltering the tea juice, and collecting the filtrate; The filtering comprises filtering with a filter screen or filter bag having an aperture range of 250-350 meshes, and collecting the filtrate; The dialysis includes filtering through a membrane with a pore size of 100-200 nm, and collecting the dialysate; The microfiltration includes filtering with a membrane having a pore size of 0.4-0.55 μm, and collecting the filtrate; Step 3, concentrating, purifying and ultracentrifuging the filtrate to obtain tea extracellular vesicles; The purification comprises the steps of purifying through a size exclusion chromatography column and collecting the eluate; The ultracentrifugation specifically includes the following steps: centrifuging the eluate during purification at 1500-2500g for 25-35min; centrifuging the supernatant at 8000-12000g for 40-50min and then microfiltering; centrifuging the filtrate at 80000-120000g for 65-75min; resuspending the precipitate in PBS buffer and centrifuging it at 80000-120000g for 65-75min to obtain tea extracellular vesicles.

2. Use of the tea extracellular vesicles according to claim 1 in the preparation of a medicament for treating atopic dermatitis, It is characterized in that The components of the enzyme solution are: 1.5-2.5wt% pectinase, 3-5wt% cellulase, and 0.4-0.8mol / L mannitol.

3. Use of the tea extracellular vesicles according to claim 1 in the preparation of a medicament for treating atopic dermatitis, It is characterized in that The volume fraction of ethanol in the ethanol solution is 70-80%.

4. Use of the tea extracellular vesicles according to claim 1 in the preparation of a medicament for treating atopic dermatitis, It is characterized in that The medicine also includes pharmaceutical additives.